Gastrointestinal Stromal Tumor Market

Market Overview:

The 7 major gastrointestinal stromal tumor markets reached a value of US$ 493.6 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 810.2 Million by 2034, exhibiting a growth rate (CAGR) of 4.61% during 2024-2034.

The gastrointestinal stromal tumor market has been comprehensively analyzed in IMARC's new report titled "Gastrointestinal Stromal Tumor Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Gastrointestinal stromal tumor refers to a rare type of neoplasm that originates in the gastrointestinal tract, particularly in the small intestine or stomach. This disease arises from specialized cells called interstitial cells of Cajal (ICC) that regulate the movement of food through the digestive system. The symptoms of the ailment can vary based on the size and area of the tumor. Individuals suffering from this illness may experience abdominal pain or discomfort, gastrointestinal bleeding, blood in the stool, nausea, bloating, vomiting, loss of appetite, a palpable mass or swelling, feeling of fullness or early satiety, unintentional weight loss, etc. The diagnosis of the ailment typically involves a combination of medical history evaluation, physical examination, and tissue sampling. Immunohistochemistry and genetic testing can also be performed to detect specific markers and mutations associated with this condition. Furthermore, several imaging studies, such as positron emission tomography (PET) scans, magnetic resonance imaging (MRI), endoscopic ultrasound (EUS), etc., are utilized to determine if the tumor has spread to other parts of the body.

The increasing prevalence of genetic mutations, causing uncontrolled growth and division of the ICC, which lead to the formation of tumors, is primarily driving the gastrointestinal stromal tumor market. In addition to this, the widespread utilization of radiofrequency ablation technique, a minimally invasive procedure that uses heat generated by high-frequency radio waves to destroy cancerous cells, is also creating a positive outlook for the market. Moreover, the emerging popularity of proton pump inhibitors, including omeprazole and pantoprazole, to reduce the production of stomach acid, alleviate heartburn, and manage gastrointestinal symptoms associated with the illness is further bolstering the market growth. Apart from this, the escalating adoption of embolization therapy, since it aims to block the blood supply to the tumors, thereby making them deprived of oxygen and nutrients, is acting as another significant growth-inducing factor. Furthermore, the inflating application of targeted therapies, like imatinib, sunitinib, regorafenib, etc., to treat advanced or metastatic disease conditions by inhibiting the activity of abnormal proteins produced by the genetic mutations is expected to drive the gastrointestinal stromal tumor market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the gastrointestinal stromal tumor market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for gastrointestinal stromal tumor and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the gastrointestinal stromal tumor market in any manner.

Recent Developments:

• In June 2024, Ascentage Pharma presented updated clinical data on olverembatinib (HQP1351), a third-generation tyrosine kinase inhibitor (TKI), in patients with TKI-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) at the 60th American Society of Clinical Oncology (ASCO) Annual Meeting. The oral report includes the most recent results, which confirm the promising efficacy and tolerable safety of olverembatinib in SDH-deficient GIST.

Key Highlights:

• Gastrointestinal stromal tumors (GISTs) account for fewer than 1% of all gastrointestinal tumors and are uncommon compared to other types of gastrointestinal tumors due to the type of tissue from which they originate.
• GISTs are the most prevalent nonepithelial or mesenchymal tumors in the gastrointestinal tract (80%), accounting for 5% of all sarcomas. 
• GIST affects between 4000 and 6000 persons in the United States each year.
• Globally, the incidence of GIST is around 1.5 per 100,000 persons.
• GISTs are more common among adults over the age of 50.

Drugs:

Qinlock (Ripretinib) is an orally administered switch-control kinase inhibitor designed for the treatment of advanced gastrointestinal stromal tumor, or GIST, in patients who have previously had treatment with three or more kinase inhibitors, including imatinib.

PLX9486 is a selective tyrosine kinase inhibitor that targets KIT exon 17 mutations, including D816V. Imatinib-resistant GIST patients typically have both primary and secondary KIT mutations, including those on exons 17 and 13, making it challenging to achieve broad therapeutic KIT inhibition. Combining PLX9486, a type 1 KIT inhibitor with activity against exon 17 mutations, and sunitinib, a type 2 KIT inhibitor with activity against exon 13 mutations, may provide significant clinical benefit compared to type I or II inhibitors alone.

DS-6157a is a potential first-in-class GPR20 (G protein-coupled receptor 20) targeting antibody-drug conjugate (ADC) in patients with advanced gastrointestinal stromal tumor (GIST) who have progressed on, or are intolerant to, standard treatment. This therapeutic candidate uses Daiichi Sankyo's patented DXd ADC technology, which is made up of a humanized anti-GPR20 monoclonal antibody linked to a new topoisomerase I inhibitor payload via a tetrapeptide.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the gastrointestinal stromal tumor market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the gastrointestinal stromal tumor market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current gastrointestinal stromal tumor marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the gastrointestinal stromal tumor market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the gastrointestinal stromal tumor market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the gastrointestinal stromal tumor market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of gastrointestinal stromal tumor across the seven major markets?
• What is the number of prevalent cases (2018-2034) of gastrointestinal stromal tumor by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of gastrointestinal stromal tumor by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with gastrointestinal stromal tumor across the seven major markets?
• What is the size of the gastrointestinal stromal tumor patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of gastrointestinal stromal tumor?
• What will be the growth rate of patients across the seven major markets?

Gastrointestinal Stromal Tumor: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for gastrointestinal stromal tumor drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the gastrointestinal stromal tumor market?
• What are the key regulatory events related to the gastrointestinal stromal tumor market?
• What is the structure of clinical trial landscape by status related to the gastrointestinal stromal tumor market?
• What is the structure of clinical trial landscape by phase related to the gastrointestinal stromal tumor market?
• What is the structure of clinical trial landscape by route of administration related to the gastrointestinal stromal tumor market?